Loading…
Statistically significant results achieved for primary and key secondary endpoints.
Lyra Therapeutics, Inc. announced on June 02, 2025 Lyra Therapeutics announced positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 for the treatment of chronic rhinosinusitis (CRS), achieving statistically significant results for primary and key secondary endpoints, with results compared to sham control.
The announcement cited -1.13; p=0.0078, -0.90; p=0.0209, -8.7; p=0.0101, -6.4; p=0.0456, -22.4 points, -2.15; p=0.1809, -1.13; p=0.0837, -8.7; p=0.1331, -6.07; p=0.1127, -0.33; p=0.2159, and -0.16; p=0.3494.
LYRA THERAPEUTICS INC has a free float of 1,506,600 shares and 1,774,900 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.